Initium Venture Capital Appoints Garrett Lindemann Ph.D. Venture Analyst, Plans for Silicon Valley Office

Share Article

Dr. Lindemann will assist expansion in Life Sciences.

Phoenix/San Jose (PRWEB) September 1, 2005 – Initium Venture Capital (Initium) today announced the addition of Dr. Garrett Lindemann as Venture Analyst for Life Sciences.

Dr. Lindemann joins Initium as an independent consultant serving the Biotech, Pharmaceuticals, and Medical Device sectors. His recent assignments include serving multiple private and public companies in North America and Europe where he led business planning, business development, product development and regulatory efforts. Prior to launching his consulting firm, Dr. Lindemann was a senior scientist at Roche Diagnostics and Vice President of Research and Development for a start-up pharmaceutical company. Lindemann holds a Ph.D. in Molecular Genetics from the University of Kansas, Lawrence, Kansas, and a B.S. in Biology from St John’s University, Collegeville, Minnesota.

"We are extremely pleased to have Garrett Lindemann on the Initium team. We have established a good working relationship over the past few years in early stage life science projects around the world," said Mark Montgomery, Managing Partner of Initium Venture Capital. "Garrett’s deep knowledge and experience in drug development, medical devices, and genomics, from the corporate, consultant, and start-up perspective, is an ideal match for Initium’s current and future projects."

Currently, Initium works with early stage ventures in Information Technology and Life Sciences with a particular emphasis on multi-disciplinary spin outs from leading labs. The firm frequently contracts with emerging technology companies in providing the full range of commercialization services, including business planning, business development, team development, and lead investor in the A round syndication. Initium plans to open a Silicon Valley office later this year led by founding partner Mark Montgomery.

Dr. Lindemann comments: "I am delighted to join the Initium team. The firm has earned an excellent reputation as a hands-on investor and a leader in early stage venture capital. I intend to leverage my knowledge and experience in helping Initium expand our portfolio in exceptional Life Science opportunities emerging from the lab."

Media Contact: Mark Montgomery (Initium)

Web Site:

About Initium Venture Capital

Initium is a private early stage venture capital firm whose primary mission is to assist entrepreneurs, engineers, and scientists in all facets of building sustainable technology companies by serving market demand and maximizing shareholder value.

Initium specializes in multi-disciplinary, or Convergence technologies, within the Life Science and Information Technology sectors.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mark Montgomery
Visit website